Article Text


Oesophageal II
PWE-027 HALO radiofrequency ablation for squamous high grade dysplasia and early squamous cell carcinoma: outcomes form the UK HALO radiofrequency ablation registry
  1. R J Haidry1,2,
  2. J Dunn1,
  3. M Banks2,
  4. A Gupta1,
  5. M A Butt1,
  6. H Smart3,
  7. P Bhandari4,
  8. L-A Smith5,
  9. R Willert6,
  10. G Fullarton7,
  11. M Di Pietro8,
  12. I Penman9,
  13. M Novelli10,
  14. L B Lovat1,2
  1. 1Department of Surgery, National Medical Laser Centre, London, UK
  2. 2Department of Gastroenterology, University College Hospital, London, UK
  3. 3Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK
  4. 4Department of Gastroenterology, Princess Alexandra Hospital, Portsmouth, UK
  5. 5Department of Gastroenterology, Bradford Teaching Hospital, Bradford, UK
  6. 6Department of Gastroenterology, Central Manchester University Hospital NHS foundation Trust, Manchester, UK
  7. 7Department of Surgery, Royal Infirmary, Glasgow, Glasgow, UK
  8. 8Department of Gastroenterology, Adednbrooke's Hospital, Cambridge, Cambridge, UK
  9. 9Department of Gastroenterology, Royal Infirmary, Edinburgh, UK
  10. 10Department of Histopathology, University College Hospital, London, UK


Introduction Squamous Cell Cancer (SCC) of the oesophagus has a poor prognosis with 5-year survival at 10%. Squamous high grade dysplasia (HGD) is the precursor lesion to SCC. Risk of progression to SCC with Squamous HGD can be 65% at 5 years. Radiofrequency ablation (RFA) is a minimally invasive ablation technique with proven efficacy for early neoplasia in Barrett's Oesophagus.

Methods Prospective multicenter registry of patients undergoing RFA for Squamous HGD and early carcinoma in situ (CIS) from eight UK centers. Nodular lesions were removed by endoscopic mucosal resection before RFA. Treatment consisted of a single ablation at 12 J/cm2. Patients were followed-up 3 monthly and repeat biopsies taken. Those with residual dysplasia underwent RFA 3 months later until 12 months where they were assessed for treatment success or failure.

Results 25 patients have undergone ablation for squamous HGD/CIS. We report on 17 patients to have completed protocol. Mean length of dysplastic epithelium ablated was 5 cm (1–14). Mean time to protocol completion was 8.7 months. CR-HGD was seen in 59% of patients and CR-D in 47% at end of protocol biopsy with mean of 1.4 RFA treatments (1–3). All those with successful outcomes remain free of dysplasia at most recent biopsy, median follow-up 10.6 months (2–36) from first treatment. At protocol completion, six of 17 patients (35%) had progressed to invasive cancer and referred for surgery or chemo-radiotherapy. Three patients (18%) required dilatations for oesophageal structuring after first treatment. Two of these patients have required serial dilatations thereafter with an average of four dilatations per patient.

Conclusion Squamous HGD and CIS are very aggressive pathologies as evidenced by the fact a third of patients progressed to invasive disease despite RFA. The role of RFA in these patients remains unclear. In our series 47% of patients responded to RFA & have reassuringly remained free of dysplasia at last follow-up. These figures are lower than limited published data to date but in our series an emphasis was placed on restaging carefully after each treatment to assess for progression. As our experience grows with confidence in identifying these lesions more accurately and increasing the frequency and number of ablations administered over the protocol period, dysplasia reversal rates will be expected to increase.

Competing interests None declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.